Why the study?
What are the long-term outcomes and lead failure rates in patients with recalled Sprint Fidelis ICD leads managed according to guidelines?
What are the long-term outcomes and lead failure rates in patients with recalled Sprint Fidelis ICD leads managed according to guidelines?
Guideline-directed management of patients with recalled Sprint Fidelis ICD leads is effective, with lead failures detected and managed without lead-related mortality.
Answers are grounded in this paper and cite their sources.
Supports guideline-directed management of recalled Sprint Fidelis leads without lead-related mortality; leaves open need for larger prospective validation.
BACKGROUND: Over the last several years significant rises in the use of implanted cardioverter-defibrillators (ICD) have also resulted in a number of associated complications. This number includes lead failure. Sprint Fidelis (SF) ICD lead is regarded as a lead with elevated failure risk. Every center acting in accordance with the guidelines should observe patients more thoroughly especially with recalled leads and run a registry of their follow-up. The aim of this research was to present follow-up of the patients with SF leads (types 6948, 6949) from a single implantation center. METHODS: There were 36 SF leads implanted in 36 patients. Mean follow-up period was 76 months (IQR 40.3-86.8). Patients were subjected to regular check-ups in 3 to 6 month intervals. RESULTS: Patients were implanted at a median age of 66.5 years and majority of them had ischemic cardiomyopathy (72%). A majority of the studied population were men (72.2%). Predominantly dual-chamber ICD (ICD-DR) were implanted (50% ICD-DR vs. 47.2% ICD-VR). The guidelines for management of patients implanted with SF were fully implemented. During the follow-up 14 (38.9%) patients died. No deaths were noted that could be attributed to lead failure. In 5 cases lead failure was identified and of these 4 leads were replaced. Median time from implantation to the detection of lead dysfunction was 52 months (IQR 49; 83). The symptoms of failure consisted of: inappropriate shocks, alternating ventricular lead signal, or loss of ventricular stimulation. CONCLUSIONS: The follow-up of patients with recalled SF leads in a single center supports that implementation SF management guidelines could be effective in clinical practice.
No takes yet. Share an insight, caveat, or question.
Grabowski et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: